X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BioSenic intends to use the net proceeds to prepare for an IND application with FDA for the Phase 3 clinical study with Arscimed, an oral arsenic trioxide (OATO) in the first-line treatment of chronic graft-versus-host disease (cGvHD).
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gestys Santé Biotech
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 02, 2024
Details:
The agreement aims for the development of the first oral formulation of ArsciCor (arsenic troxide) in the field of several targeted autoimmune diseases, including for cGvHD treatment.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: ArsciCor
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Phebra
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 15, 2024
Details:
The proceeds of the financing will essentially contribute to continuing to advance the clinical development of BioSenic’s lead asset, its ATO product, Arscimed (arsenic trioxide), in the treatment of chronic graft versus host disease (cGvHD).
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ABO Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 08, 2024
Details:
ATO (arsenic trioxide) is administered daily by IV infusions, which is investigated for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious disease.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: OATO
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
ALLOB is an allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. It is being developed for delayed-union fractures and spinal fusion procedures.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate osteoarthritis pain.
Lead Product(s): Clonidine,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: JTA-004
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Arscimed® (arsenic trioxide), is a able to radically modify the autoimmune cascade and normalise the immune system without causing nonspecific immunosuppressionbeing studied for cGvHD.
Lead Product(s): Arsenic Trioxide,Metal ion
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate osteoarthritis pain.
Lead Product(s): JTA-004
Therapeutic Area: Musculoskeletal Product Name: JTA-004
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
ALLOB is an allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. It is being developed for delayed-union fractures and spinal fusion procedures.
Lead Product(s): Allogeneic Bone Cell Therapy
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
The BioSenic autoimmune platform has been constructed to target systemic autoimmune diseases using arsenic trioxide (Arscimed, ATO). This uses ATO’s first-in-class mechanism of action as an active anti-inflammatory and immunomodulatory agent.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
